Small Molecules
8 January 2013
Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection7 January 2013
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin7 January 2013
Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint in Pivotal Phase III Psoriasis Trials4 January 2013
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis4 January 2013
MediciNova Provides Development Update3 January 2013
Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets3 January 2013
Repros’ Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids3 January 2013
Cerulean Announces First Patient Dosed in Phase 2 Pharmacodynamic Study of CRLX101 in Advanced Gastric Cancer3 January 2013
EnVivo Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial Program of EVP-0962 in Alzheimer’s Disease3 January 2013
Celtaxsys Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary InflammationNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports